Increased aggression, improved spatial memory, and reduced anxiety-like behaviour in adult male mice exposed to fluoxetine early in life

Developmental Neuroscience

Volumn 36, Issue 5, 2014, Pages 396-408

  Kiryanova, Veronika ^a,b   Dyck, Richard H ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

Aggression; Anxiety; Behaviour; Development; Exposure, perinatal; Fluoxetine; Mouse; Pregnancy; Selective serotonin reuptake inhibitor; Serotonin

Indexed keywords

FLUOXETINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGGRESSION; AMNESIA; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANXIETY; ARTICLE; C57BL 6 MOUSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG METABOLISM; ELEVATED PLUS MAZE TEST; FLUID INTAKE; LIMIT OF DETECTION; MALE; MOTOR PERFORMANCE; MOUSE; NONHUMAN; PRENATAL EXPOSURE; PREPULSE INHIBITION; PRIORITY JOURNAL; SPATIAL MEMORY; ANIMAL; CONDITIONED REFLEX; DRUG EFFECTS; FEAR; FEMALE; MATERNAL BEHAVIOR; MOTOR ACTIVITY; PATHOPHYSIOLOGY; PHYSIOLOGY; PREGNANCY;

AGGRESSION; ANIMALS; ANXIETY; BEHAVIOR, ANIMAL; CONDITIONING, CLASSICAL; FEAR; FEMALE; FLUOXETINE; MALE; MATERNAL BEHAVIOR; MICE; MOTOR ACTIVITY; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; SEROTONIN UPTAKE INHIBITORS; SPATIAL MEMORY;

EID: 84927689946     PISSN: 03785866     EISSN: 14219859     Source Type: Journal    
DOI: 10.1159/000363102     Document Type: Article

References (101)

1. Noble RE. Depression in women. Metabolism. 2005; 54: 49-52
2. Kallen B. Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med. 2004; 158: 312-316
3. Andrade SE, Raebel MA, Brown J, Lane K, Livingston J, Boudreau D, Rolnick SJ, Roblin D, Smith DH, Willy ME, Staffa JA, Platt R. Use of antidepressant medications during pregnancy: a multisite study. Am J Obstet Gynecol. 2008; 198: 194e1-e5
4. Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry. 2006; 63: 898-906
5. Cooper WO, Willy ME, Pont SJ, Ray WA. Increasing use of antidepressants in pregnancy. Am J Obstet Gynecol. 2007; 196: 544e1-e5
6. Kim J, Riggs KW, Misri S, Kent N, Oberlander T, Grunau R, Fitzgerald C, Rurak D. Stereoselective disposition of fluoxetine and norfluoxetine during pregnancy and breast-feeding. Br J Clin Pharmacol. 2006; 61: 155-163
7. Rampono J, Simmer K, Ilett KF, Hackett LP, Doherty DA, Elliot R, Kok CH, Coenen A, Forman T. Placental transfer of SSRI and SNRI antidepressants and effects on the neonate. Pharmacopsychiatry. 2009; 42: 95-100
8. Heikkinen T, Ekblad U, Palo P, Laine K. Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation. Clin Pharmacol Ther. 2003; 73: 330-337
9. Lester BM, Cucca J, Andreozzi L, Flanagan P, Oh W. Possible association between fluoxetine hydrochloride and colic in an infant. J Am Acad Child Adolesc Psychiatry. 1993; 32: 1253-1255
10. Gaspar P, Cases O, Maroteaux L. The developmental role of serotonin: news from mouse molecular genetics. Nat Rev Neurosci. 2003; 4: 1002-1012
11. McCobb DP, Haydon PG, Kater SB. Dopamine and serotonin inhibition of neurite elongation of different identified neurons. J Neurosci Res. 1988; 19: 19-26
12. Chubakov AR, Gromova EA, Konovalov GV, Sarkisova EF, Chumasov EI. The effects of serotonin on the morpho-functional development of rat cerebral neocortex in tissue culture. Brain Res. 1986; 369: 285-297
13. Lauder JM, Krebs H. Serotonin as a differentiation signal in early neurogenesis. Dev Neurosci. 1978; 1: 15-30
14. Vitalis T, Parnavelas JG. The role of serotonin in early cortical development. Dev Neurosci. 2003; 25: 245-256
15. Gentile S, Galbally M. Prenatal exposure to antidepressant medications and neurodevelopmental outcomes: a systematic review. J Affect Disord. 2011; 128: 1-9
16. Kiryanova V, McAllister BB, Dyck RH. Longterm outcomes of developmental exposure to fluoxetine: a review of the animal literature. Dev Neurosci. 2013; 35: 437-439
17. Bairy KL, Madhyastha S, Ashok KP, Bairy I, Malini S. Developmental and behavioral consequences of prenatal fluoxetine. Pharmacology. 2007; 79: 1-11
18. Olivier JDA, Valles A, van Heesch F, Afrasiab-Middelman A, Roelofs JJPM, Jonkers M, Peeters EJ, Korte-Bouws GAH, Dederen JP, Kiliaan AJ, Martens G, Schubert D, Homberg J. Fluoxetine administration to pregnant rats increases anxiety-related behavior in the offspring. Psychopharmacology (Berl) 2011; 217: 419-432
19. McAllister BB, Kiryanova V, Dyck RH. Behavioural outcomes of perinatal maternal fluoxetine treatment. Neuroscience. 2012; 226: 356-366
20. Lisboa SF, Oliveira PE, Costa LC, Venancio EJ, Moreira EG. Behavioral evaluation of male and female mice pups exposed to fluoxetine during pregnancy and lactation. Pharmacology. 2007; 80: 49-56
21. Karpova NN, Lindholm J, Pruunsild P, Timmusk T, Castren E. Long-lasting behavioural and molecular alterations induced by early postnatal fluoxetine exposure are restored by chronic fluoxetine treatment in adult mice. Eur Neuropsychopharmacol. 2009; 19: 97-108
22. Mendes-da-Silva C, de Souza SL, Barreto-Medeiros JM, de Freitas-Silva SR, Antunes DEC, Cunha ADU, Ribas VR, de Franca MFS, Nogueira MI, Manhaes-de-Castro R. Neonatal treatment with fluoxetine reduces depressive behavior induced by forced swim in adult rats. Arq Neuropsiquiatr. 2002; 60: 928-931
23. Noorlander CW, Ververs FFT, Nikkels PGJ, van Echteld CJA, Visser GHA, Smidt MP. Modulation of serotonin transporter function during fetal development causes dilated heart cardiomyopathy and lifelong behavioral abnormalities. PLoS One. 2008; 3: e2782
24. Ansorge MS, Morelli E, Gingrich JA. Inhibition of serotonin but not norepinephrine transport during development produces delayed, persistent perturbations of emotional behaviors in mice. J Neurosci. 2008; 28: 199-207
25. Gouvea TS, Morimoto HK, de Faria MJ, Moreira EG, Gerardin DC. Maternal exposure to the antidepressant fluoxetine impairs sexual motivation in adult male mice. Pharmacol Biochem Behav. 2008; 90: 416-419
26. Kiryanova V, Smith VM, Dyck RH, Antle MC. The effects of perinatal fluoxetine treatment on the circadian system of the adult mouse. Psychopharmacology (Berl) 2013; 225: 743-751
27. Rayen I, Steinbusch H, Charlier TD, Pawluski JL. Developmental fluoxetine exposure and prenatal stress alter sexual differentiation of the brain and reproductive behavior in male rat offspring. Psychoneuroendocrinology. 2013; 38: 1618-1629
28. Rayen I, Steinbusch H, Charlier TD, Pawluski JL. Developmental fluoxetine exposure facilitates sexual behavior in female offspring. Psychopharmacology (Berl) 2014; 231: 123-133
29. Forcelli PA, Heinrichs SC. Teratogenic effects of maternal antidepressant exposure on neural substrates of drug-seeking behavior in offspring. Addict Biol. 2008; 13: 52-62
30. Singh Y, Jaiswal AK, Singh M, Bhattacharya SK. Effect of prenatal diazepam, phenobarbital, haloperidol and fluoxetine exposure on foot shock induced aggression in rats. Indian J Exp Biol. 1998; 36: 1023-1024
31. Brunner HG, Nelen M, Breakefield XO, Ropers HH, van Oost BA. Abnormal behavior associated with a point mutation in the structural gene for monoamine oxidase A. Science. 1993; 262: 578-580
32. Cases O, Seif I, Grimsby J, Gaspar P, Chen K, Pournin S, Muller U, Aguet M, Babinet C, Shih JC. Aggressive behavior and altered amounts of brain serotonin and norepinephrine in mice lacking MAOA. Science. 1995; 268: 1763-1766
33. Popova N, Skrinskaya Y, Amstislavskaya T, Vishnivetskaya G, Seif I, de Meier E. Behavioral characteristics of mice with genetic knockout of monoamine oxidase type A. Neurosci Behav Physiol. 2001; 31: 597-602
34. Vishnivetskaya GB, Skrinskaya JA, Seif I, Popova NK. Effect of MAO A deficiency on different kinds of aggression and social investigation in mice. Aggress Behav. 2007; 33: 1-6
35. Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, Benjamin J, Muller CR, Hamer DH, Murphy DL. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science. 1996; 274: 1527-1531
36. Greenberg BD, Li Q, Lucas FR, Hu S, Sirota LA, Benjamin J, Lesch KP, Hamer D, Murphy DL. Association between the serotonin transporter promoter polymorphism and personality traits in a primarily female population sample. Am J Med Genet. 2000; 96: 202-216
37. Osher Y, Hamer D, Benjamin J. Association and linkage of anxiety-related traits with a functional polymorphism of the serotonin transporter gene regulatory region in Israeli sibling pairs. Mol Psychiatry. 2000; 5: 216-219
38. Nietzer SL, Bonn M, Jansen F, Heiming RS, Lewejohann L, Sachser N, Asan ES, Lesch KP, Schmitt AG. Serotonin transporter knockout and repeated social defeat stress: impact on neuronal morphology and plasticity in limbic brain areas. Behav Brain Res. 2011; 220: 42-54
39. Wellman CL, Izquierdo A, Garrett JE, Martin KP, Carroll J, Millstein R, Lesch KP, Murphy DL, Holmes A. Impaired stress-coping and fear extinction and abnormal corticolimbic morphology in serotonin transporter knockout mice. J Neurosci. 2007; 27: 684-691
40. Hirano K, Kimura R, Sugimoto Y, Yamada J, Uchida S, Kato Y, Hashimoto H, Yamada S. Relationship between brain serotonin transporter binding, plasma concentration and behavioural effect of selective serotonin reuptake inhibitors. Br J Pharmacol. 2005; 144: 695-702
41. Capello CF, Bourke CH, Ritchie JC, Stowe ZN, Newport DJ, Nemeroff A, Owens MJ. Serotonin transporter occupancy in rats exposed to serotonin reuptake inhibitors in utero or via breast milk. J Pharmacol Exp Ther. 2011; 339: 275-285
42. Homberg JR, Olivier JD, Blom T, Arentsen T, van Brunschot C, Schipper P, Korte-Bouws G, van Luijtelaar G, Reneman L. Fluoxetine exerts age-dependent effects on behavior and amygdala neuroplasticity in the rat. PLoS One. 2011; 6: e16646
43. Morrison JL, Riggs KW, Rurak DW. Fluoxetine during pregnancy: impact on fetal development. Reprod Fertil Dev. 2005; 17: 641-650
44. Renwick AG. The use of safety or uncertainty factors in the setting of acute reference doses. Food Addit Contam. 2000; 17: 627-635
45. Clancy B, Kersh B, Hyde J, Darlington RB, Anand KJ, Finlay BL. Web-based method for translating neurodevelopment from laboratory species to humans. Neuroinformatics. 2007; 5: 79-94
46. Romijn HJ, Hofman MA, Gramsbergen A. At what age is the developing cerebral cortex of the rat comparable to that of the full-Term newborn human baby?. Early Hum Dev. 1991; 26: 61-67
47. Raap DK, Garcia F, Muma NA, Wolf WA, Battaglia G, van de Kar LD. Sustained desensitization of hypothalamic 5-hydroxytryptamine1A receptors after discontinuation of fluoxetine: inhibited neuroendocrine responses to 8-hydroxy-2-(dipropylamino)tetralin in the absence of changes in Gi/o/z proteins. J Pharmacol Exp Ther. 1999; 288: 561-567
48. Chourbaji S, Hoyer C, Richter SH, Brandwein C, Pfeiffer N, Vogt MA, Vollmayr B, Gass P. Differences in mouse maternal care behavior: is there a genetic impact of the glucocorticoid receptor?. PLoS One. 2011; 6: e19218
49. Dierssen M, Fotaki V, Martinez de Lagran M, Gratacos M, Arbones M, Fillat C, Estivill X. Neurobehavioral development of two mouse lines commonly used in transgenic studies. Pharmacol Biochem Behav. 2002; 73: 19-25
50. Handley SL, Mithani S. Effects of á-Adrenoceptor agonists and antagonists in a maze-exploration model of 'fear'-motivated behaviour. Naunyn Schmiedebergs Arch Pharmacol. 1984; 327: 1-5
51. Lister RG. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology (Berl) 1987; 92: 180-185
52. Brown R. Differences in measures of exploration and fear in MHC-congenic C57BL/6J and B6-H-2K mice. Behav Genet. 1999; 29: 263
53. Cruz AP, Frei F, Graeff FG. Ethopharmacological analysis of rat behavior on the elevated plus-maze. Pharmacol Biochem Behav. 1994; 49: 171-176
54. Rodgers RJ, Johnson NJ. Factor analysis of spatiotemporal and ethological measures in the murine elevated plus-maze test of anxiety. Pharmacol Biochem Behav. 1995; 52: 297-303
55. Miczek KA, Krsiak M. Drug effects on agonistic behavior; in Thompson T, Dews PB (eds): Advances in Behavioral Pharmacology. New York, Academic Press, 1979, vol 2, pp 87-162
56. Crawley JN. What's Wrong with My Mouse?. Behavioral Phenotyping of Transgenic and Knockout Mice. New York, Wiley-Liss, 2000
57. Litvin Y, Blanchard DC, Pentkowski NS, Blanchard RJ A pinch or a lesion: a reconceptualization of biting consequences in mice. Aggress Behav. 2007; 33: 545-551
58. de Boer SF, Lesourd M, Mocaer E, Koolhaas JM. Selective antiaggressive effects of alnespirone in resident-intruder test are mediated via 5-hydroxytryptamine1A receptors: a comparative pharmacological study with 8-hydroxy-2-dipropylaminotetralin, ipsapirone, buspirone, eltoprazine, and WAY-100635. J Pharmacol Exp Ther. 1999; 288: 1125-1133
59. Homberg JR, Pattij T, Janssen MC, Ronken E, de Boer SF, Schoffelmeer AN, Cuppen E. Serotonin transporter deficiency in rats improves inhibitory control but not behavioural flexibility. Eur J Neurosci. 2007; 26: 2066-2073
60. Metz GA, Whishaw IQ. Cortical and subcortical lesions impair skilled walking in the ladder rung walking test: a new task to evaluate fore- And hindlimb stepping, placing, and coordination. J Neurosci Methods. 2002; 115: 169-179
61. Farr TD, Liu L, Colwell KL, Whishaw IQ, Metz GA. Bilateral alteration in stepping pattern after unilateral motor cortex injury: a new test strategy for analysis of skilled limb movements in neurological mouse models. J Neurosci Methods. 2006; 153: 104-113
62. Vorhees CV, Williams MT. Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nat Protoc. 2006; 1: 848-858
63. Ansorge MS, Zhou M, Lira A, Hen R, Gingrich JA. Early-life blockade of the 5-HT transporter altersemotional behavior in adult mice. Science. 2004; 306: 879-881
64. Caccia S, Cappi M, Fracasso C, Garattini S. Influence of dose and route of administration on the kinetics of fluoxetine and its metabolite norfluoxetine in the rat. Psychopharmacology (Berl) 1990; 100: 509-514
65. Brown AP, Dinger N, Levine BS. Stress produced by gavage administration in the rat. Contemp Top Lab Anim Sci. 2000; 39: 17-21
66. Germann PG, Ockert D. Granulomatous inflammation of the oropharyngeal cavity as a possible cause for unexpected high mortality in a Fischer 344 rat carcinogenicity study. Lab Anim Sci. 1994; 44: 338-343
67. Murphy SJ, Smith P, Shaivitz AB, Rossberg MI, Hurn PD. The effect of brief halothane anesthesia during daily gavage on complications and body weight in rats. Contemp Top Lab Anim Sci. 2001; 40: 9-12
68. Ryabinin AE, Wang YM, Finn DA. Different levels of Fos immunoreactivity after repeated handling and injection stress in two inbred strains of mice. Pharmacol Biochem Behav. 1999; 63: 143-151
69. Vallee M, Mayo W, Dellu F, le Moal M, Simon H, Maccari S. Prenatal stress induces high anxiety and postnatal handling induces low anxiety in adult offspring: correlation with stress-induced corticosterone secretion. J Neurosci. 1997; 17: 2626-2636
70. Green MK, Rani CS, Joshi A, Soto-Pina AE, Martinez PA, Frazer A, Strong R, Morilak DA. Prenatal stress induces long term stress vulnerability, compromising stress response systems in the brain and impairing extinction of conditioned fear after adult stress. Neuroscience. 2011; 192: 438-451
71. Lee EJ, Son GH, Chung S, Lee S, Kim J, Choi S, Kim K. Impairment of fear memory consolidation in maternally stressed male mouse offspring: evidence for nongenomic glucocorticoid action on the amygdala. J Neurosci. 2011; 31: 7131-7140
72. Alonso SJ, Castellano MA, Quintero M, Navarro E. Action of antidepressant drugs on maternal stress-induced hypoactivity in female rats. Methods Find Exp Clin Pharmacol. 1999; 21: 291-295
73. Rayen I, van den Hove DL, Prickaerts J, Steinbusch HW, Pawluski JL. Fluoxetine during development reverses the effects of prenatal stress on depressive-like behavior and hippocampal neurogenesis in adolescence. PLoS One. 2011; 6: e24003
74. Ordian NE, Pivina SG, Fedotova IO, Akulova VK. Comparative efficacy of selective serotonin reuptake inhibitors in young prenatally stressed female rats (in Russian). Eksp Klin Farmakol. 2010; 73: 7-10
75. Knaepen L, Rayen I, Charlier TD, Fillet M, Houbart V, van Kleef M, Steinbusch HW, Patijn J, Tibboel D, Joosten EA, Pawluski JL. Developmental fluoxetine exposure normalizes the long-Term effects of maternal stress on post-operative pain in Sprague-Dawley rat offspring. PLoS One. 2013; 8: e57608
76. Einarson TR, Kennedy D, Einarson A. Do findings differ across research design?. The case of antidepressant use in pregnancy and malformations. J Popul Ther Clin Pharmacol. 2012; 19: 334-348
77. Holmes A. Targeted gene mutation approaches to the study of anxiety-like behavior in mice. Neurosci Biobehav Rev. 2001; 25: 261-273
78. Shih JC, Chen K, Ridd MJ. Monoamine oxidase: from genes to behavior. Annu Rev Neurosci. 1999; 22: 197-217
79. Hansson SR, Mezey E, Hoffman BJ. Serotonin transporter messenger RNA in the developing rat brain: early expression in serotonergic neurons and transient expression in non-serotonergic neurons. Neuroscience. 1998; 83: 1185-1201
80. Lebrand C, Cases O, Wehrle R, Blakely RD, Edwards RH, Gaspar P. Transient developmental expression of monoamine transporters in the rodent forebrain. J Comp Neurol. 1998; 401: 506-524
81. Verney C, Lebrand C, Gaspar P. Changing distribution of monoaminergic markers in the developing human cerebral cortex with special emphasis on the serotonin transporter. Anat Rec. 2002; 267: 87-93
82. Vorhees CV, Acuff-Smith KD, Schilling MA, Fisher JE, Moran MS, Buelke-Sam J A developmental neurotoxicity evaluation of the effects of prenatal exposure to fluoxetine in rats. Fundam Appl Toxicol. 1994; 23: 194-205
83. Lewis RJ, Johnson RD, Angier MK. The distribution of fluoxetine and norfluoxetine in postmortem fluids and tissues. Oklahoma City, Federal Aviation Administration Civil Aerospace Medical Institute, 2007, pp 1-12
84. Bauer S, Monk C, Ansorge M, Gyamfi C, Myers M. Impact of antenatal selective serotonin reuptake inhibitor exposure on pregnancy outcomes in mice. Am J Obstet Gynecol. 2010; 203: 375e1-e4
85. Zheng J, Xu DF, Li K, Wang HT, Shen PC, Lin M, Cao XH, Wang R. Neonatal exposure to fluoxetine and fluvoxamine alters spine density in mouse hippocampal CA1 pyramidal neurons. Int J Clin Exp Pathol. 2011; 4: 162-168
86. Nagano M, Liu M, Inagaki H, Kawada T, Suzuki H. Early intervention with fluoxetine reverses abnormalities in the serotonergic system and behavior of rats exposed prenatally to dexamethasone. Neuropharmacology. 2012; 63: 292-300
87. Oakeshott JG. Social dominance, aggressiveness and mating success among male house mice (Mus musculus) . Oecologia. 1974; 15: 143-158
88. Kamil AC, Roitblat HL. The ecology of foraging behavior: implications for animal learning and memory. Annu Rev Psychol. 1985; 36: 141-169
89. Pawluski JL, Rayen I, Niessen NA, Kristensen S, van Donkelaar EL, Balthazart J, Steinbusch HW, Charlier TD. Developmental fluoxetine exposure differentially alters central and peripheral measures of the HPA system in adolescent male and female offspring. Neuroscience. 2012; 220: 131-141
90. da-Silva VA, Altenburg SP, Malheiros LR, Thomaz TG, Lindsey CJ. Postnatal development of rats exposed to fluoxetine or venlafaxine during the third week of pregnancy. Braz J Med Biol Res. 1999; 32: 93-98
91. Pawluski JL, Charlier TD, Fillet M, Houbart V, Crispin HT, Steinbusch HW, van den Hove DL. Chronic fluoxetine treatment and maternal adversity differentially alter neurobehavioral outcomes in the rat dam. Behav Brain Res. 2012; 228: 159-168
92. Talge NM, Neal C, Glover V; Early Stress, Translational Research and Prevention Science Network: Fetal and Neonatal Experience on Child and Adolescent Mental Health: Antenatal maternal stress and longterm effects on child neurodevelopment: how and why?. J Child Psychol Psychiatry. 2007; 48: 245-261
93. Kinney DK, Munir KM, Crowley DJ, Miller AM. Prenatal stress and risk for autism. Neurosci Biobehav Rev. 2008; 32: 1519-1532
94. Ishiwata H, Shiga T, Okado N. Selective serotonin reuptake inhibitor treatment of early postnatal mice reverses their prenatal stress-induced brain dysfunction. Neuroscience. 2005; 133: 893-901
95. Sareen J, Cox BJ, Clara I, Asmundson GJG: The relationship between anxiety disorders and physical disorders in the US National Comorbidity Survey. Depress Anxiety. 2005; 21: 193-202
96. Steiner M. Serotonin, depression, and cardiovascular disease: sex-specific issues. Acta Physiol. 2011; 203: 253-258
97. Vogelzangs N, Seldenrijk A, Beekman ATF, van Hout HPJ, de Jonge P, Penninx BWJH: Cardiovascular disease in persons with depressive and anxiety disorders. J Affect Disord. 2010; 125: 241-248
98. El-Gabalawy R, Mackenzie CS, Shooshtari S, Sareen J. Comorbid physical health conditions and anxiety disorders: a populationbased exploration of prevalence and health outcomes among older adults. Gen Hosp Psychiatry. 2011; 33: 556-564
99. Brown PJ, Roose SP. Age and anxiety and depressive symptoms: the effect on domains of quality of life. Int J Geriatr Psychiatry. 2011; 26: 1260-1266
100. Ford MT, Cerasoli CP, Higgins JA, Decesare AL. Relationships between psychological, physical, and behavioural health and work performance: a review and meta-Analysis. Work Stress. 2011; 25: 185-204
101. Wenzel A, Graff-Dolezal J, Macho M, Brendle JR. Communication and social skills in socially anxious and nonanxious individuals in the context of romantic relationships. Behav Res Ther. 2005; 43: 505-519